<p>分析師對 Teva Pharmaceutical Indus（紐約證券交易所代碼：TEVA）在過去一個季度的評級從看漲到看跌不等，共有 11 位分析師提供了相關信息。</p>
<p>在下面的表格中，您將找到他們最近評級的總結，揭示了過去 30 天情緒的變化，並與前幾個月進行了比較。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析師通過對 12 個月價格目標的評估提供了更深入的見解，顯示出平均目標為 35.36 美元，最高預估為 40.00 美元，最低預估為 28.00 美元。這一上升趨勢顯而易見，目前的平均值較之前的 30.22 美元的平均價格目標增長了 17.01%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769713231_0_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="價格目標圖表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769713231_0_0.png"/></p>
<h2>深入分析分析師評級：全面探索</h2>
<p>通過對最近分析師行動的深入分析，清晰描繪了 Teva Pharmaceutical Indus 在金融專家中的認知。下面的總結概述了關鍵分析師、他們最近的評估以及對評級和價格目標的調整。</p>
<table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Louise Chen</td>
<td>Scotiabank</td>
<td>上調</td>
<td>行業表現優於大盤</td>
<td>$40.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Les Sulewski</td>
<td>Truist Securities</td>
<td>上調</td>
<td>買入</td>
<td>$38.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>上調</td>
<td>買入</td>
<td>$40.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>上調</td>
<td>超配</td>
<td>$40.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Matt Dellatorre</td>
<td>Goldman Sachs</td>
<td>上調</td>
<td>買入</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>上調</td>
<td>超配</td>
<td>$35.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>上調</td>
<td>買入</td>
<td>$32.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Barclays</td>
<td>宣佈</td>
<td>超配</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Matt Dellatorre</td>
<td>Goldman Sachs</td>
<td>上調</td>
<td>買入</td>
<td>$31.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Scotiabank</td>
<td>宣佈</td>
<td>行業表現優於大盤</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>上調</td>
<td>超配</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
</tbody>
</table>
<h3>關鍵見解：</h3>
<ul>
<li><strong>採取的行動：</strong> 分析師對市場條件和公司表現的變化作出反應，頻繁更新他們的建議。無論是 ‘維持’，‘上調’ 還是 ‘下調’ 他們的立場，反映了他們對 Teva Pharmaceutical Indus 最近發展的反應。這些信息提供了分析師對公司當前狀態的看法快照。</li>
<li><strong>評級：</strong> 深入評估，分析師賦予定性值，從 ‘表現優於大盤’ 到 ‘表現不及大盤’。這些評級傳達了對 Teva Pharmaceutical Indus 相對於更廣泛市場的表現預期。</li>
<li><strong>價格目標：</strong> 分析師預測價格目標的變動，提供 Teva Pharmaceutical Indus 未來價值的估計。檢查當前和之前的目標提供了分析師不斷變化的預期的見解。</li>
</ul>
<p>通過這些分析師評估與其他財務指標的結合，可以幫助全面理解 Teva Pharmaceutical Indus 的市場地位。保持信息靈通，並通過我們的評級表做出數據驅動的決策。</p>
<p>隨時瞭解 Teva Pharmaceutical Indus 的分析師評級。</p>
<h2>發現 Teva Pharmaceutical Indus：更深入的瞭解</h2>
<p>Teva Pharmaceutical，總部位於以色列，是全球領先的仿製藥製造商。Teva 的銷售一半來自北美，並佔美國仿製藥處方總數的高個位數百分比。它在歐洲、日本、俄羅斯和以色列也有顯著的市場份額。除了仿製藥，Teva 在三個主要治療領域擁有創新藥物和生物類似藥的產品組合：中樞神經系統（Copaxone、Ajovy 和 Austedo）；呼吸系統（Qvar 和 ProAir）；以及腫瘤學（Truxima、Herzuma 和 Bendeka/Treanda）。Teva 還銷售活性藥物成分，提供合同製造服務，並擁有 Anda，一家美國的仿製藥和特種藥物分銷商。</p>
<h3>Teva Pharmaceutical Indus 的財務表現</h3>
<p><strong>市值分析：</strong> 反映出較小的規模，該公司的市值低於行業平均水平。這可能歸因於增長預期或運營能力等因素。</p>
<p><strong>收入增長：</strong> Teva Pharmaceutical Indus 在 2025 年 9 月 30 日的表現顯著，收入增長率達到 <strong>3.42%</strong>。這表明公司在收入方面有了顯著的提升。與行業同行相比，該公司的增長率低於醫療保健行業的平均水平。</p>
<p><strong>淨利潤率：</strong> Teva Pharmaceutical Indus 的淨利潤率低於行業標準，表明在實現強勁盈利能力方面面臨困難。淨利潤率為 <strong>9.67%</strong>，公司可能在有效控制成本方面遇到挑戰。</p>
<p><strong>股本回報率（ROE）：</strong> Teva Pharmaceutical Indus 的 ROE 表現突出，超過行業平均水平。ROE 為 <strong>6.15%</strong>，表明公司有效利用股本並展現出強勁的財務表現。</p>
<p><strong>資產回報率（ROA）：</strong> 該公司的 ROA 低於行業基準，表明在有效利用資產方面可能存在困難。ROA 為 <strong>1.08%</strong>，公司可能需要解決從資產中產生令人滿意的回報的挑戰。</p>
<p><strong>債務管理：</strong> 梯瓦製藥的債務與股本比率顯著高於行業平均水平，達到 <strong>2.35</strong>。這表明其對借款資金的依賴程度較高，令人對財務槓桿產生擔憂。</p>
<h2>理解分析師評級的相關性</h2>
<p>分析師是銀行和金融系統中的專家，通常針對特定股票或特定行業進行報告。這些人研究公司的財務報表，參加電話會議和會議，並與相關內部人士交談，以確定股票的分析師評級。通常，分析師每季度會對每隻股票進行評級。</p>
<p>除了標準評估外，一些分析師還會對增長預期、收益和收入等指標進行預測，為投資者提供額外的指導。使用分析師評級的用户應注意，這些專業建議受到人類觀點的影響，可能會存在變動。</p>
<p>本文由 Benzinga 的自動內容引擎生成，並經過編輯審核。</p>

<p>分析師對梯瓦製藥（NYSE:TEVA）的評級顯示出看漲和看跌情緒的混合，過去一個季度共有 11 位分析師提供了見解。12 個月的平均目標價格已上升至 35.36 美元，比之前的目標上漲了 17.01%。主要分析師提高了他們的評級和目標價格，表明市場預期積極。梯瓦作為一家領先的仿製藥製造商，收入增長了 3.42%，但面臨淨利潤率為 9.67% 和高達 2.35 的債務股本比率的挑戰，顯示出對借款資金的依賴。分析師評級對投資者評估市場情緒和公司表現至關重要</p>

<p>Analysts' ratings for Teva Pharmaceutical Indus (NYSE: TEVA) over the last quarter vary from bullish to bearish, as provided by 11 analysts.</p>
<div class="lb-trans"><p>分析師對 Teva Pharmaceutical Indus（紐約證券交易所代碼：TEVA）在過去一個季度的評級從看漲到看跌不等，共有 11 位分析師提供了相關信息。</p>
</div><p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<div class="lb-trans"><p>在下面的表格中，您將找到他們最近評級的總結，揭示了過去 30 天情緒的變化，並與前幾個月進行了比較。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $35.36, a high estimate of $40.00, and a low estimate of $28.00. This upward trend is evident, with the current average reflecting a 17.01% increase from the previous average price target of $30.22.</p>
<div class="lb-trans"><p>分析師通過對 12 個月價格目標的評估提供了更深入的見解，顯示出平均目標為 35.36 美元，最高預估為 40.00 美元，最低預估為 28.00 美元。這一上升趨勢顯而易見，目前的平均值較之前的 30.22 美元的平均價格目標增長了 17.01%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769713231_0_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1769713231_0_0.png"/></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<div class="lb-trans"><h2>深入分析分析師評級：全面探索</h2>
</div><p>A clear picture of Teva Pharmaceutical Indus's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通過對最近分析師行動的深入分析，清晰描繪了 Teva Pharmaceutical Indus 在金融專家中的認知。下面的總結概述了關鍵分析師、他們最近的評估以及對評級和價格目標的調整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Louise Chen</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$40.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Les Sulewski</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$38.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Matt Dellatorre</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$35.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Matt Dellatorre</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$31.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Louise Chen</td>
<td>Scotiabank</td>
<td>上調</td>
<td>行業表現優於大盤</td>
<td>$40.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Les Sulewski</td>
<td>Truist Securities</td>
<td>上調</td>
<td>買入</td>
<td>$38.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>上調</td>
<td>買入</td>
<td>$40.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>上調</td>
<td>超配</td>
<td>$40.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Matt Dellatorre</td>
<td>Goldman Sachs</td>
<td>上調</td>
<td>買入</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>上調</td>
<td>超配</td>
<td>$35.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>上調</td>
<td>買入</td>
<td>$32.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Barclays</td>
<td>宣佈</td>
<td>超配</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Matt Dellatorre</td>
<td>Goldman Sachs</td>
<td>上調</td>
<td>買入</td>
<td>$31.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Scotiabank</td>
<td>宣佈</td>
<td>行業表現優於大盤</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>上調</td>
<td>超配</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>關鍵見解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Teva Pharmaceutical Indus. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Teva Pharmaceutical Indus compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Teva Pharmaceutical Indus's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>採取的行動：</strong> 分析師對市場條件和公司表現的變化作出反應，頻繁更新他們的建議。無論是 ‘維持’，‘上調’ 還是 ‘下調’ 他們的立場，反映了他們對 Teva Pharmaceutical Indus 最近發展的反應。這些信息提供了分析師對公司當前狀態的看法快照。</li>
<li><strong>評級：</strong> 深入評估，分析師賦予定性值，從 ‘表現優於大盤’ 到 ‘表現不及大盤’。這些評級傳達了對 Teva Pharmaceutical Indus 相對於更廣泛市場的表現預期。</li>
<li><strong>價格目標：</strong> 分析師預測價格目標的變動，提供 Teva Pharmaceutical Indus 未來價值的估計。檢查當前和之前的目標提供了分析師不斷變化的預期的見解。</li>
</ul>
</div><p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Teva Pharmaceutical Indus's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<div class="lb-trans"><p>通過這些分析師評估與其他財務指標的結合，可以幫助全面理解 Teva Pharmaceutical Indus 的市場地位。保持信息靈通，並通過我們的評級表做出數據驅動的決策。</p>
</div><p>Stay up to date on Teva Pharmaceutical Indus analyst ratings.</p>
<div class="lb-trans"><p>隨時瞭解 Teva Pharmaceutical Indus 的分析師評級。</p>
</div><h2>Discovering Teva Pharmaceutical Indus: A Closer Look</h2>
<div class="lb-trans"><h2>發現 Teva Pharmaceutical Indus：更深入的瞭解</h2>
</div><p>Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.</p>
<div class="lb-trans"><p>Teva Pharmaceutical，總部位於以色列，是全球領先的仿製藥製造商。Teva 的銷售一半來自北美，並佔美國仿製藥處方總數的高個位數百分比。它在歐洲、日本、俄羅斯和以色列也有顯著的市場份額。除了仿製藥，Teva 在三個主要治療領域擁有創新藥物和生物類似藥的產品組合：中樞神經系統（Copaxone、Ajovy 和 Austedo）；呼吸系統（Qvar 和 ProAir）；以及腫瘤學（Truxima、Herzuma 和 Bendeka/Treanda）。Teva 還銷售活性藥物成分，提供合同製造服務，並擁有 Anda，一家美國的仿製藥和特種藥物分銷商。</p>
</div><h3>Teva Pharmaceutical Indus's Financial Performance</h3>
<div class="lb-trans"><h3>Teva Pharmaceutical Indus 的財務表現</h3>
</div><p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 反映出較小的規模，該公司的市值低於行業平均水平。這可能歸因於增長預期或運營能力等因素。</p>
</div><p><strong>Revenue Growth:</strong> Teva Pharmaceutical Indus's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of <strong>3.42%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<div class="lb-trans"><p><strong>收入增長：</strong> Teva Pharmaceutical Indus 在 2025 年 9 月 30 日的表現顯著，收入增長率達到 <strong>3.42%</strong>。這表明公司在收入方面有了顯著的提升。與行業同行相比，該公司的增長率低於醫療保健行業的平均水平。</p>
</div><p><strong>Net Margin:</strong> Teva Pharmaceutical Indus's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>9.67%,</strong> the company may encounter challenges in effective cost control.</p>
<div class="lb-trans"><p><strong>淨利潤率：</strong> Teva Pharmaceutical Indus 的淨利潤率低於行業標準，表明在實現強勁盈利能力方面面臨困難。淨利潤率為 <strong>9.67%</strong>，公司可能在有效控制成本方面遇到挑戰。</p>
</div><p><strong>Return on Equity (ROE):</strong> Teva Pharmaceutical Indus's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>6.15%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<div class="lb-trans"><p><strong>股本回報率（ROE）：</strong> Teva Pharmaceutical Indus 的 ROE 表現突出，超過行業平均水平。ROE 為 <strong>6.15%</strong>，表明公司有效利用股本並展現出強勁的財務表現。</p>
</div><p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>1.08%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<div class="lb-trans"><p><strong>資產回報率（ROA）：</strong> 該公司的 ROA 低於行業基準，表明在有效利用資產方面可能存在困難。ROA 為 <strong>1.08%</strong>，公司可能需要解決從資產中產生令人滿意的回報的挑戰。</p>
</div><p><strong>Debt Management:</strong> Teva Pharmaceutical Indus's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>2.35</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<div class="lb-trans"><p><strong>債務管理：</strong> 梯瓦製藥的債務與股本比率顯著高於行業平均水平，達到 <strong>2.35</strong>。這表明其對借款資金的依賴程度較高，令人對財務槓桿產生擔憂。</p>
</div><h2>Understanding the Relevance of Analyst Ratings</h2>
<div class="lb-trans"><h2>理解分析師評級的相關性</h2>
</div><p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.</p>
<div class="lb-trans"><p>分析師是銀行和金融系統中的專家，通常針對特定股票或特定行業進行報告。這些人研究公司的財務報表，參加電話會議和會議，並與相關內部人士交談，以確定股票的分析師評級。通常，分析師每季度會對每隻股票進行評級。</p>
</div><p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<div class="lb-trans"><p>除了標準評估外，一些分析師還會對增長預期、收益和收入等指標進行預測，為投資者提供額外的指導。使用分析師評級的用户應注意，這些專業建議受到人類觀點的影響，可能會存在變動。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自動內容引擎生成，並經過編輯審核。</p>
</div>

11 位分析師對梯瓦製藥的評估：你需要了解的內容